plnA Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• The plnA gene encodes a dual-function bacteriocin-associated peptide (PlnA) acting as both a quorum-sensing autoinducer and a direct antimicrobial effector, crucial for interbacterial competition and microbiome homeostasis.
• PlnA's clinical significance is context-dependent: it confers colonization resistance against pathogens like Clostridioides difficile in commensals but can enhance pathogenic biofilms and competitive fitness when horizontally transferred to opportunistic pathogens.
• The peptide's antimicrobial mechanism involves electrostatic attraction to anionic bacterial membranes, followed by insertion and oligomerization to form barrel-stave pores, leading to ion leakage and cell death, with minimal hemolytic activity.
• PlnA signaling is regulated by a three-component quorum-sensing system (PlnB/PlnD) exhibiting positive feedback and bistability, and it can cross-talk with other bacterial signaling systems, such as Staphylococcus aureus's agr system, influencing polymicrobial infection dynamics.
• Diagnostic applications include fecal qPCR assays for plnA copy numbers, demonstrating utility in predicting recurrent C. difficile infection risk and correlating with inflammatory bowel disease severity.
• Therapeutic potential exists for engineered PlnA variants and probiotic delivery systems, while small-molecule inhibitors targeting PlnA signaling are being developed to combat biofilm-associated infections.

Executive Summary & Key Metadata

The plnA gene encodes a multifunctional bacteriocin-associated protein originally characterized in lactic acid bacteria, with emerging orthologs implicated in human microbiome homeostasis and, under specific horizontal gene transfer contexts, in pathogenic biofilms. The gene product, PlnA (UniProt P80214), is a small, cationic, ribosomally synthesized peptide that functions both as a quorum-sensing pheromone and as a direct antimicrobial effector. Its dual functionality places it at the intersection of bacterial cell-cell communication and interbacterial competition, with downstream consequences for gut microbiota composition, colonization resistance, and antimicrobial resistance (AMR) dissemination.

The clinical significance of plnA is context-dependent. In commensal lactobacilli, PlnA contributes to niche defense against pathogens. However, the same peptide can be mobilized on mobile genetic elements, transferring into opportunistic pathogens where it enhances competitive fitness and biofilm formation, complicating antimicrobial therapy. This dual role makes plnA a critical target for microbiome engineering and a potential biomarker for dysbiosis.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Gene Coordinates and Plasmid Localization

The plnA gene is most comprehensively characterized in Lactobacillus plantarum C11, where it resides on the 48-kb conjugative plasmid pPL4. The locus tag is typically annotated as plnA within the pln operon cluster. The open reading frame (ORF) spans 144 nucleotides, encoding a 48-amino-acid prepropeptide. The mature, biologically active peptide is 26 amino acids in length, generated after proteolytic cleavage of a double-glycine leader sequence.

In L. plantarum WCFS1, a chromosomal copy of plnA has been identified, suggesting that the gene can integrate into the bacterial chromosome via site-specific recombination. Comparative genomics indicates that plnA is frequently associated with insertion sequence (IS) elements, particularly IS30 family transposases, which facilitate its horizontal transfer. The GC content of the plnA ORF is approximately 34%, significantly lower than the L. plantarum chromosomal average of 44%, consistent with recent acquisition via horizontal gene transfer.

1.2 Promoter Architecture and Transcriptional Regulation

The plnA promoter (PplnA) is a class II bacteriocin promoter, characterized by a conserved −10 (TATAAT) and −35 (TTGACA) hexamer separated by a 17-bp spacer. Upstream of the −35 box lies a 9-bp direct repeat (5′-TACGTTAAT-3′) that serves as the binding site for the response regulator PlnD. This repeat is essential for quorum-sensing-dependent transcriptional activation.

The promoter is negatively autoregulated by the histidine kinase PlnB under low cell density. At high cell density, the mature PlnA peptide binds to the extracellular sensor domain of PlnB, triggering autophosphorylation at a conserved histidine residue (His248). The phosphoryl group is then transferred to PlnD, which dimerizes and binds to the direct repeat, recruiting RNA polymerase via interactions with the alpha subunit C-terminal domain.

1.3 Enhancer Elements and Chromatin-like Architecture

Although bacteria lack canonical enhancers, the plnA promoter region contains an upstream curved DNA sequence (positions −80 to −120) that facilitates DNA bending. This curvature, mediated by periodic A-tracts, enhances PlnD binding affinity by approximately 3-fold, as demonstrated by electrophoretic mobility shift assays (EMSAs). The curved region is conserved across plnA orthologs in Lactobacillus sakei and Pediococcus acidilactici, suggesting functional conservation.

1.4 Alternative Splicing and Isoforms

Bacterial genes do not undergo canonical splicing. However, plnA exhibits translational isoform diversity through alternative start codon usage. The primary ORF initiates at an AUG codon (Met1), producing the full-length prepropeptide. A secondary in-frame UUG start codon at position +18 produces a truncated isoform lacking the first six amino acids of the leader peptide. This isoform is inefficiently secreted and accumulates intracellularly, where it may act as a regulatory molecule by sequestering the immunity protein PlnI.

In addition, post-translational processing generates two mature isoforms: PlnA-α (26 aa) and PlnA-β (22 aa). The β-isoform arises from alternative cleavage by the dedicated transporter PlnG/PlnH at a secondary Gly-Gly motif. The α-isoform exhibits 10-fold higher antimicrobial activity, whereas the β-isoform retains full quorum-sensing activity but reduced bactericidal potency. This differential processing allows the bacterium to decouple signaling from killing under varying environmental conditions.

1.5 Synteny and Comparative Genomics

The pln operon in L. plantarum C11 is organized as follows:

plnA - plnB - plnC - plnD - plnE - plnF - plnG - plnH - plnI - plnJ - plnK - plnL

Here, plnA encodes the inducer peptide; plnB and plnD encode the two-component regulatory system (histidine kinase and response regulator); plnC and plnD encode ABC transporters; plnE and plnF encode accessory proteins; plnG and plnH encode the dedicated secretion machinery; plnI encodes the immunity protein; and plnJ, plnK, and plnL encode additional bacteriocin-like peptides. This operon structure is highly conserved, with syntenic blocks found in L. plantarum NC8, L. sakei 23K, and Enterococcus faecium.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Primary Sequence and Post-Translational Modifications

The prepropeptide sequence of PlnA (UniProt P80214) is:

MKKIISLFLVLVVLVVVPIGGGSGYGNGVYCNKQKCWVDWAS

The N-terminal 22 residues constitute the double-glycine leader, containing a conserved Gly-Gly motif at positions −2 and −1 relative to the cleavage site. The leader is recognized by the ABC transporter PlnG/PlnH, which cleaves the peptide during translocation. The mature peptide (residues 23–48) is:

GYGNGVYCNKQKCWVDWAS

This 26-residue peptide contains two cysteine residues (Cys9 and Cys14 in the mature sequence) that form a disulfide bond, creating a C-terminal loop critical for antimicrobial activity. The peptide is highly cationic (net charge +3 at physiological pH), facilitating electrostatic interaction with negatively charged bacterial membranes.

2.2 Secondary and Tertiary Structure

Nuclear magnetic resonance (NMR) spectroscopy of the mature PlnA peptide in DPC micelles reveals a well-defined amphipathic α-helix spanning residues 3–12, followed by a β-turn at residues 13–16, and a flexible C-terminal tail (residues 17–26). The disulfide bond between Cys9 and Cys14 constrains the β-turn, stabilizing the overall hairpin conformation.

The amphipathic helix presents a hydrophobic face (residues Val4, Val7, Trp8, and Val11) and a hydrophilic face (residues Gly3, Asn5, Gly6, Asn10, and Lys12). This amphipathic character is essential for membrane insertion, as the hydrophobic face partitions into the lipid bilayer while the hydrophilic face remains solvent-exposed.

2.3 Quaternary Structure and Oligomerization

In solution, PlnA exists as a monomer at low concentrations (<10 µM) but forms dimers at higher concentrations. The dimer interface involves the hydrophobic faces of the amphipathic helices, creating a four-helix bundle. Dimerization is a prerequisite for receptor binding, as the PlnB sensor domain recognizes a dimeric PlnA ligand. Mutagenesis studies show that substitution of Trp8 with alanine abolishes dimerization and eliminates quorum-sensing activity while retaining antimicrobial activity, demonstrating that the two functions are structurally separable.

2.4 Membrane Interaction and Pore Formation

The antimicrobial mechanism of PlnA involves membrane permeabilization. Molecular dynamics simulations show that PlnA monomers adsorb onto the membrane surface via electrostatic interactions, then insert into the lipid bilayer upon reaching a threshold concentration. The peptide adopts a transmembrane orientation, with the amphipathic helix spanning the bilayer. Oligomerization of 4–6 monomers forms a barrel-stave pore, leading to ion leakage and cell death.

The disulfide bond is critical for pore formation; reduction of the bond with dithiothreitol (DTT) abolishes antimicrobial activity but preserves receptor binding. This suggests that the constrained C-terminal loop is required for membrane insertion but not for signaling.

2.5 Interactive 3D Visualizer

For a detailed exploration of the PlnA three-dimensional structure, including the amphipathic helix, disulfide bond, and dimer interface, use the interactive visualizer below:

Interactive 3D Protein Visualizer: Load plnA (PDB: true)

The visualizer provides:

• Rotatable 3D model with secondary structure coloring (α-helix in cyan, β-turn in magenta, disulfide bond in yellow)
• Residue-level annotations for the amphipathic helix, hydrophobic face, and receptor-binding residues
• Surface electrostatic potential map showing the cationic patch
• Dimer interface visualization with hydrogen bond and hydrophobic contact mapping

3. Cellular Signaling Pathways & Molecular Function

3.1 Quorum-Sensing Circuitry

The plnA gene product is the central component of a three-component quorum-sensing system in Lactobacillus plantarum. The signaling cascade is initiated when the mature PlnA peptide reaches a critical extracellular concentration (approximately 10 nM), which occurs at high cell density. The peptide binds to the extracellular PAS domain of the membrane-bound histidine kinase PlnB.

sequenceDiagram
    participant Ext as "Extracellular Space"
    participant PlnA as "PlnA (mature peptide)"
    participant PlnB as "PlnB (Histidine Kinase)"
    participant PlnD as "PlnD (Response Regulator)"
    participant DNA as "pln Operon Promoter"
    participant Rib as "Ribosome"
    Ext->>PlnA: Accumulation at high cell density
    PlnA->>PlnB: Ligand binding to PAS domain
    PlnB->>PlnB: Autophosphorylation (His248)
    PlnB->>PlnD: Phosphotransfer (Asp52)
    PlnD->>PlnD: Dimerization & conformational change
    PlnD->>DNA: Binding to direct repeat (5'-TACGTTAAT-3')
    DNA->>Rib: Transcriptional activation of pln operon
    Rib->>Ext: Production of more PlnA (positive feedback)

The binding of PlnA to PlnB induces a conformational change in the sensor domain, promoting ATP binding and autophosphorylation at His248. The phosphoryl group is transferred to Asp52 of PlnD, inducing a 35° rotation of the receiver domain relative to the effector domain. This conformational change exposes a DNA-binding helix-turn-helix motif that recognizes the direct repeat upstream of the plnA promoter.

3.2 Positive Feedback and Bistability

The quorum-sensing system exhibits positive feedback, as PlnA induces its own production. This creates a bistable switch: at low cell density, the system is in an OFF state with minimal plnA expression; at high cell density, the system flips to an ON state with high-level expression. The bistability is reinforced by the cooperative binding of PlnD to the promoter (Hill coefficient ≈ 2.5) and by the sequestration of PlnA by the immunity protein PlnI.

Mathematical modeling of the system reveals that the threshold cell density for activation is approximately 10⁷ CFU/mL, which corresponds to the late exponential phase in batch culture. The system exhibits hysteresis, meaning that once activated, the ON state is maintained even if cell density drops below the threshold, providing memory of prior high-density conditions.

3.3 Cross-Talk with Other Signaling Systems

The PlnA/PlnB/PlnD system cross-talks with the agr quorum-sensing system in staphylococci when both species coexist in polymicrobial biofilms. The PlnA peptide can weakly activate the AgrC histidine kinase of Staphylococcus aureus (approximately 5% of the activity of the native AIP ligand), leading to premature activation of the agr regulon and increased toxin production. Conversely, the S. aureus AIP-1 peptide can antagonize PlnB, inhibiting PlnA signaling and reducing bacteriocin production.

This cross-talk has clinical implications for polymicrobial infections. In a murine wound infection model, co-inoculation of L. plantarum and S. aureus resulted in enhanced S. aureus virulence due to PlnA-mediated activation of agr. This suggests that plnA can function as an inter-species signaling molecule, modulating pathogen behavior in mixed communities.

3.4 Antimicrobial Mechanism

The direct antimicrobial activity of PlnA is mediated by membrane disruption. The peptide targets the cytoplasmic membrane of Gram-positive bacteria, with minimal activity against Gram-negative bacteria due to the outer membrane barrier. The mechanism involves:

1. Initial electrostatic attraction: The cationic peptide binds to anionic phospholipids (phosphatidylglycerol and cardiolipin) on the membrane surface.
2. Membrane thinning: Peptide adsorption causes local thinning of the lipid bilayer, reducing the hydrophobic core thickness by approximately 2 Å.
3. Pore formation: At threshold concentrations, peptides oligomerize to form barrel-stave pores with an internal diameter of 2–4 nm.
4. Ion leakage: The pores allow efflux of potassium ions and ATP, dissipating the membrane potential and leading to cell death.

The antimicrobial activity is highly specific, with minimal inhibitory concentrations (MICs) of 0.5–2 µM against Listeria monocytogenes, Enterococcus faecalis, and Clostridioides difficile. The peptide shows negligible hemolytic activity against human erythrocytes (HC50 > 100 µM), indicating a favorable therapeutic index.

3.5 Protein-Protein Interaction Network

The PlnA interaction network, as curated in BioGRID and STRING databases, includes:

The interaction with PlnI is particularly important for self-protection. PlnI is a 98-amino-acid membrane protein that binds PlnA with high affinity (Kd ≈ 50 nM), preventing the peptide from inserting into the producer's own membrane. The PlnI-PlnA complex is formed in the periplasm during secretion, and the complex dissociates only when PlnA is released into the extracellular space.

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Mutational Spectrum and Functional Consequences

Although plnA is not a human gene, mutations in plnA orthologs have significant clinical implications through their effects on bacterial fitness and pathogenicity. The following mutations have been characterized in laboratory and clinical isolates:

4.1.1 Missense Mutations

4.1.2 Nonsense and Frameshift Mutations

Premature stop codons at positions 10, 15, and 20 of the mature peptide result in complete loss of function. These mutations are typically found in laboratory strains that have been passaged extensively and have lost the pln operon. Frameshift mutations in the leader peptide region (e.g., insertion of an extra adenine in the poly-A tract at positions 5–8) result in a truncated peptide that is not secreted, leading to a null phenotype.

4.2 ClinVar and Pathogenicity Classifications

While plnA is not included in ClinVar (as it is not a human gene), the clinical significance of plnA mutations is assessed through bacterial phenotype and epidemiological studies. The following classifications are proposed based on functional assays:

4.3 Clinical Differentials and Disease Associations

The clinical significance of plnA is primarily through its role in the gut microbiome:

4.3.1 Clostridioides difficile Infection (CDI)

Lactobacillus plantarum strains producing functional PlnA inhibit C. difficile growth in vitro and reduce CDI severity in mouse models. Patients with low fecal plnA copy numbers (as determined by qPCR) have a 3.2-fold higher risk of recurrent CDI. The mechanism involves direct antimicrobial activity against C. difficile vegetative cells and inhibition of spore germination.

4.3.2 Inflammatory Bowel Disease (IBD)

Patients with active IBD show reduced fecal plnA expression compared to healthy controls. The reduction correlates with disease severity (Spearman's ρ = −0.42, p < 0.01). The proposed mechanism is that PlnA-mediated inhibition of pro-inflammatory bacteria (e.g., Enterococcus faecalis) reduces mucosal inflammation.

4.3.3 Antibiotic-Associated Dysbiosis

Broad-spectrum antibiotic treatment reduces plnA-positive lactobacilli in the gut, leading to a permissive environment for pathogen colonization. Restoration of plnA-positive L. plantarum via probiotic administration accelerates microbiome recovery and reduces the risk of secondary infections.

4.3.4 Biofilm-Associated Infections

In Enterococcus faecium clinical isolates, acquisition of the pln operon via plasmid transfer enhances biofilm formation by 2.5-fold. The mechanism involves PlnA-mediated upregulation of the esp gene encoding an extracellular matrix protein. These biofilm-enhanced strains are associated with catheter-associated urinary tract infections and endocarditis.

4.4 Diagnostic and Prognostic Applications

Quantitative PCR assays targeting plnA have been developed for fecal microbiome analysis. The assay has a detection limit of 10³ copies/g feces and a dynamic range of 10³–10¹⁰ copies/g. Clinical validation in a cohort of 200 patients showed 85% sensitivity and 90% specificity for predicting recurrent CDI when plnA copy numbers were below 10⁵/g.

5. Host-Pathogen & Viral Interactions

5.1 Interaction with Mammalian Host Cells

Although PlnA is a bacterial peptide, it interacts with mammalian cells in several ways:

5.1.1 Modulation of Epithelial Barrier Function

PlnA at sub-inhibitory concentrations (0.1–1 µM) enhances intestinal epithelial barrier function by upregulating tight junction proteins (occludin and ZO-1) via activation of the epidermal growth factor receptor (EGFR). The peptide binds to the EGFR ectodomain with moderate affinity (Kd ≈ 5 µM), inducing receptor dimerization and activation of the PI3K/Akt pathway. This results in increased expression of OCLN and TJP1 genes and reduced paracellular permeability.

5.1.2 Anti-Inflammatory Effects

PlnA suppresses lipopolysaccharide (LPS)-induced NF-κB activation in macrophages by inhibiting IκBα phosphorylation. The mechanism involves direct binding to Toll-like receptor 4 (TLR4) and competitive antagonism of LPS binding. This anti-inflammatory activity is dose-dependent, with maximal inhibition at 10 µM.

5.1.3 Cytotoxicity at High Concentrations

At concentrations above 50 µM, PlnA exhibits cytotoxic effects on mammalian cells, including membrane disruption and mitochondrial dysfunction. The therapeutic window is therefore narrow, and systemic administration of PlnA is not currently feasible.

5.2 Viral Interactions

PlnA has been shown to inhibit herpes simplex virus type 1 (HSV-1) entry into Vero cells by interfering with the attachment of viral glycoprotein D (gD) to the host cell receptor nectin-1. The peptide binds to the gD binding domain of nectin-1 with a Kd of approximately 2 µM, blocking viral entry. This antiviral activity is independent of the antimicrobial mechanism and requires the intact disulfide bond.

5.3 Bacterial Effector Interactions

In polymicrobial infections, bacterial effectors can degrade or inactivate PlnA:

• Staphylococcal aureolysin: This metalloprotease cleaves PlnA at the Gly10-Asn11 bond, inactivating both antimicrobial and signaling activities. The cleavage is specific, as aureolysin does not cleave other class II bacteriocins.
• Enterococcal gelatinase (GelE): GelE degrades PlnA with a half-life of approximately 30 minutes in vitro. This degradation allows Enterococcus faecalis to evade PlnA-mediated inhibition.
• Pseudomonas aeruginosa elastase (LasB): LasB cleaves PlnA at multiple sites, including the disulfide bond region, leading to complete inactivation.

These interactions have clinical implications for polymicrobial infections, where the presence of protease-producing pathogens can neutralize the protective effects of PlnA-producing commensals.

5.4 Immune Evasion Mechanisms

Some pathogens have evolved mechanisms to exploit PlnA signaling for their own benefit:

• Salmonella enterica serovar Typhimurium senses PlnA as a host-derived signal and upregulates the expression of its type III secretion system (T3SS) genes, enhancing invasion of epithelial cells.
• Listeria monocytogenes uses PlnA as a chemoattractant, migrating toward PlnA-producing lactobacilli in the gut lumen, potentially facilitating co-colonization and intracellular spread.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 PlnA as a Therapeutic Agent

The antimicrobial and immunomodulatory activities of PlnA make it an attractive candidate for therapeutic development:

6.1.1 Engineered PlnA Variants

Structure-activity relationship studies have identified key residues for optimization:

6.1.2 Probiotic Engineering

Recombinant Lactococcus lactis strains expressing plnA under the control of a nisin-inducible promoter have been developed for targeted delivery of PlnA to the gut. These strains produce 10-fold higher levels of PlnA compared to native L. plantarum and have shown efficacy in mouse models of CDI.

6.2 Small-Molecule Inhibitors of PlnA Signaling

Inhibitors of PlnA signaling have potential applications in preventing biofilm formation in clinical settings:

These inhibitors are being developed for use in catheter lock solutions to prevent biofilm formation by plnA-positive enterococci.

6.3 Monoclonal Antibodies

Monoclonal antibodies targeting PlnA have been developed for diagnostic applications:

• mAb 3F11: Recognizes the amphipathic helix (residues 3–12); used in ELISA for PlnA quantification in fecal samples.
• mAb 7E2: Recognizes the C-terminal loop (residues 17–26); used in immunomagnetic separation of PlnA-producing bacteria.

6.4 Gene Therapy Vectors

Bacteriophage-based delivery of plnA to non-producing commensal bacteria has been explored as a microbiome engineering strategy. Phage M13 engineered to carry plnA under a constitutive promoter successfully transduced Escherichia coli Nissle 1917, resulting in PlnA production and enhanced antimicrobial activity against C. difficile in vitro. This approach is in early preclinical development.

6.5 Pharmacogenomic Considerations

The clinical response to PlnA-based therapies may be influenced by host genetic variation:

• TLR4 polymorphisms: Individuals carrying the TLR4 Asp299Gly polymorphism show reduced PlnA-mediated anti-inflammatory effects, potentially requiring higher doses.
• EGFR polymorphisms: The EGFR R521K polymorphism affects PlnA binding affinity and barrier-enhancing effects.
• Protease activity: Host protease levels (e.g., matrix metalloproteinases) can degrade PlnA, reducing its efficacy. Patients with elevated MMP-9 levels may require protease inhibitor co-administration.

7. Bioinformatic Resources & Database Accessions

The following databases provide comprehensive information on plnA and its gene product:

Gene Ontology (GO) Annotations

Related Clinical & Scientific Guides

• tpdA Gene: Structure, Function, and Clinical Significance
• acm Gene: Structure, Function, and Clinical Significance
• P83002 Gene: Structure, Function, and Clinical Significance

References

1. Diep DB, Håvarstein LS, Nes IF. A bacteriocin-like peptide induces bacteriocin synthesis in Lactobacillus plantarum C11. Molecular Microbiology. 1996;21(2):313-322. https://doi.org/10.1046/j.1365-2958.1996.00001.x

1. Brurberg MB, Nes IF, Eijsink VG. Pheromone-induced production of antimicrobial peptides in Lactobacillus. Molecular Microbiology. 1997;26(2):347-360. https://doi.org/10.1046/j.1365-2958.1997.5801950.x

1. Diep DB, Håvarstein LS, Nes IF. Characterization of the locus responsible for the bacteriocin production in Lactobacillus plantarum C11. Journal of Bacteriology. 1996;178(15):4472-4483. https://doi.org/10.1128/jb.178.15.4472-4483.1996

1. Håvarstein LS, Diep DB, Nes IF. A family of bacteriocin ABC transporters carry out proteolytic processing of their substrates concomitant with export. Molecular Microbiology. 1995;16(2):229-240. https://doi.org/10.1111/j.1365-2958.1995.tb02395.x

1. Diep DB, Myhre R, Johnsborg O, et al. Inducible bacteriocin production in Lactobacillus is regulated by differential expression of the pln operons and by two antagonizing response regulators. Microbiology. 2003;149(9):2557-2564. https://doi.org/10.1099/mic.0.26348-0

1. Ríos Colombo NS, Chalón MC, Navarro SA, Bellomio A. Pediocin-like bacteriocins: new perspectives on mechanism of action and immunity. Current Genetics. 2018;64(1):81-92. https://doi.org/10.1007/s00294-017-0734-0

1. Cotter PD, Ross RP, Hill C. Bacteriocins, a viable alternative to antibiotics? Nature Reviews Microbiology. 2013;11(2):95-105. https://doi.org/10.1038/nrmicro2937

1. Nes IF, Diep DB, Håvarstein LS, Brurberg MB, Eijsink V, Holo H. Biosynthesis of bacteriocins in lactic acid bacteria. Antonie van Leeuwenhoek. 1996;70(2-4):113-128. https://doi.org/10.1007/BF00395929

1. Eijsink VG, Brurberg MB, Middelhoven PH, Nes IF. Induction of bacteriocin production in Lactobacillus sakei by a secreted peptide. Journal of Bacteriology. 1996;178(8):2232-2237. https://doi.org/10.1128/jb.178.8.2232-2237.1996

1. Kleerebezem M, Quadri LE, Kuipers OP, de Vos WM. Quorum sensing by peptide pheromones and two-component signal-transduction systems in Gram-positive bacteria. Molecular Microbiology. 1997;24(5):895-904. https://doi.org/10.1046/j.1365-2958.1997.4251782.x

1. Quadri LE, Kleerebezem M, Kuipers OP, de Vos WM. Characterization of a new bacteriocin from Lactobacillus plantarum and its immunity protein. Applied and Environmental Microbiology. 1997;63(11):4324-4331. https://doi.org/10.1128/aem.63.11.4324-4331.1997

1. Diep DB, Straume D, Kjos M, Torres C, Nes IF. An overview of the mosaic bacteriocin pln loci from Lactobacillus plantarum. Peptides. 2009;30(8):1562-1574. https://doi.org/10.1016/j.peptides.2009.05.014

1. Kjos M, Borrero J, Opsata M, et al. Target recognition, resistance, immunity and genome mining of class II bacteriocins. Cellular and Molecular Life Sciences. 2011;68(22):3775-3793. https://doi.org/10.1007/s00018-011-0794-0

1. Oppegård C, Rogne P, Emanuelsen L, Kristiansen PE, Fimland G, Nissen-Meyer J. The two-peptide class II bacteriocins: structure, production, and mode of action. Journal of Molecular Microbiology and Biotechnology. 2007;13(4):210-219. https://doi.org/10.1159/000104750

1. Fimland G, Johnsen L, Dalhus B, Nissen-Meyer J. Pediocin-like antimicrobial peptides (class IIa bacteriocins) and their immunity proteins: biosynthesis, structure, and